Biogen (NASDAQ:BIIB – Get Rating) had its target price raised by Wedbush  from $249.00 to $263.00 in a research note issued on Monday, Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Wedbush’s target price indicates a potential downside of 10.49% from the company’s previous close. Wedbush also issued estimates for Biogen’s Q1 2023 earnings at $3.64 EPS, Q3 2023 earnings at $3.86 EPS, FY2024 earnings at $17.06 EPS, FY2025 earnings at $15.91 EPS and FY2027 earnings at $15.96 EPS.

Several other equities research analysts have also issued reports on BIIB. Morgan Stanley lowered their target price on shares of Biogen from $351.00 to $349.00 and set an “overweight” rating for the company in a report on Wednesday, April 12th. Piper Sandler raised shares of Biogen from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $280.00 to $346.00 in a research report on Monday. Royal Bank of Canada lifted their price objective on shares of Biogen from $335.00 to $350.00 in a research note on Monday, March 13th. Oppenheimer decreased their target price on shares of Biogen from $320.00 to $310.00 and set an “outperform” rating for the company in a research note on Thursday, February 16th. Finally, Cowen increased their price objective on shares of Biogen from $300.00 to $315.00 and gave the company an “outperform” rating in a report on Thursday, February 16th. Five research analysts have rated the stock with a hold rating, twenty have assigned  a buy rating and one  has issued  a strong buy rating to the company’s stock. According to data from MarketBeat, Biogen  has an average rating of “Moderate Buy” and an average target price of $322.76.

Shares of NASDAQ BIIB opened at $293.83 on Monday. The firm’s 50 day moving average price is $274.64 and its 200-day moving average price is $280.29. The company has a market cap of $42.46 billion, a PE ratio of 14.04, a P/E/G ratio of 2.47 and a beta of 0.19. Biogen has a 52-week low of $187.16 and a 52-week high of $311.88. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.58 and a current ratio of 2.99.

Biogen (NASDAQ:BIIB – Get Rating) last issued its quarterly earnings data on Wednesday, February 15th. The biotechnology company reported $4.05 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.57. Biogen had a net margin of 29.95% and a return on equity of 20.96%. The company had revenue of $2.54 billion for the quarter, compared to the consensus estimate of $2.44 billion. During the same quarter in the prior year, the firm earned $3.39 earnings per share. The firm’s revenue for the quarter was down 6.9% compared to the same quarter last year.  On average, equities research analysts expect that  Biogen will post 15.54 EPS for the current fiscal year.

In other news, insider Priya Singhal sold 91 shares of the firm’s stock in a transaction that occurred on Tuesday, April 4th. The stock was sold at an average price of $277.11, for a total value of $25,217.01. Following the completion of the sale, the insider now directly owns 2,843 shares of the company’s stock, valued at $787,823.73. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.65% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC grew its position in shares of  Biogen by 526.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 94 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 79 shares during the last quarter.  Larson Financial Group LLC purchased a new stake in shares of  Biogen during the third quarter valued at approximately $25,000.  Altshuler Shaham Ltd bought a new position in  Biogen during the fourth quarter valued at $25,000.  CVA Family Office LLC boosted its holdings in shares of  Biogen by 50.0% in the third quarter. CVA Family Office LLC now owns 105 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 35 shares during the period.  Finally, MinichMacGregor Wealth Management LLC purchased a new stake in shares of  Biogen in the fourth quarter worth $28,000. 84.40% of the stock is owned by institutional investors and hedge funds.

Biogen, Inc is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer’s disease, and FUMADERM for the treatment of severe plaque psoriasis.

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.